RxDoctor Payments Data

Muddasar Chaudry, MD

Infectious Disease · Salem, VANPI 1396795936

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations.

$1,584in general payments, 2019–2025

Across 87 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$377
  • Gilead$340
  • AbbVie$165
  • Viiv Healthcare Company$100
  • Paratek Pharmaceuticals, Inc.$93
  • Insmed, Inc.$90
  • plus $419 from 13 others

What the payments were for

  • Food & beverage$1,51996%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,584 in reported general payments places this provider in the 80th percentile of 194 infectious disease providers in Virginia.

See all infectious disease providers in Virginia

Medicare billing

Part B allowed, 2024
$205,027
Medicare patients
919
Services billed
1,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala118$481,561
Daptomycin81$193,951
GenvoyaElviteg/Cob/Emtri/Tenof Alafen24$110,420
ErtapenemErtapenem Sodium88$59,417
CompleraEmtricita/Rilpivirine/Tenof Df13$46,289
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$39,168
Lopinavir-RitonavirLopinavir/Ritonavir11$9,121
Vancomycin Hcl23$5,889
CefuroximeCefuroxime Axetil79$4,973
CeftriaxoneCeftriaxone Sodium37$4,395
Lamivudine-ZidovudineLamivudine/Zidovudine11$3,710
Doxycycline Hyclate141$2,751
Rifampin15$1,439
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav33$925
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim53$899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$340$591,980142 claims
Johnson & JohnsonComplera$64$46,28913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 194 infectious disease providers in Virginia.

Other infectious disease in Salem

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →